PT  - JOURNAL ARTICLE
AU  - Nightingale, Emily S
AU  - Pham-Minh, Ly
AU  - Bello, Isah Mohammed
AU  - Okrior, Samuel
AU  - Erbeto, Tesfaye Bedada
AU  - Baba, Marycelin
AU  - Adeneji, Adekunle
AU  - Auzenbergs, Megan
AU  - Edmunds, W John
AU  - O’Reilly, Kathleen M
TI  - Sub-national modelling of surveillance sensitivity to inform declaration of disease elimination
AID  - 10.1101/2025.01.30.25321401
DP  - 2025 Jan 01
TA  - medRxiv
PG  - 2025.01.30.25321401
4099  - http://medrxiv.org/content/early/2025/09/02/2025.01.30.25321401.short
4100  - http://medrxiv.org/content/early/2025/09/02/2025.01.30.25321401.full
AB  - A fundamental question in the global commitment to polio eradication is how long a period of absence would be consistent with regional elimination, and the safe withdrawal of the oral polio vaccine is contingent on the answer. We present a statistical framework to model the time-varying sensitivity of two key components of polio surveillance - environmental sampling and clinical cases of acute flaccid paralysis - for detecting infection on a monthly basis at the local government authority level. We use this to estimate the probability of freedom from infection (FFI) at a critical prevalence level that is consistent with interruption of transmission, given the absence of virus in collected samples. We validated this framework against two periods of poliovirus absence in Nigeria (2014-2016 and 2016-2020).Our model highlights substantial heterogeneity in surveillance sensitivity over time and space and, given this, concluded an 85% probability (95% uncertainty interval: 77.1-90.2%) of the country being free from WPV1 infection after 23 months without detection from July 2014. Detection of WPV1 in July 2016 demonstrated that circulation had indeed persisted during this time. In contrast, we conclude a probability of 98% (97.9-98.7%) by the time elimination of the serotype was officially declared in 2020.The inferred probability of FFI during both time periods was found to be consistent with the retrospectively known status of regional elimination. This supports the validity of applying this framework prospectively to inform the certification of wild poliovirus elimination from remaining endemic regions, and to determine the resolution of cVDPV2 outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by grants from the Polio Research Committee (Surveillance Modelling to Support Polio Elimination and Certification (SPEC), ref: 1432457-1) and the Bill and Melinda Gates Foundation (INV-049298). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the London School of Hygiene and Tropical Medicine (approval number: 29381, granted 18th April 2023).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDetailed disease surveillance data on which this research is based are available from the WHO Institutional Data Access/Ethics Committee for Global Polio Eradication Initiative research partners who meet the criteria for access to confidential data (http://polioeradication.org/tools-and-library/research-innovation/ grants-and-collaborations/). The code used to conduct this analysis is available in the following repository, alongside a test dataset of randomised values: https://github.com/esnightingale/polio-ffi-model https://github.com/esnightingale/polio-ffi-model